治疗 COVID-19 药物与癌症治疗药物相互作用的注意事项。
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.
机构信息
Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Crit Rev Oncol Hematol. 2020 Jul;151:102982. doi: 10.1016/j.critrevonc.2020.102982. Epub 2020 May 12.
Abstract
SARS-CoV2 infection is an emerging issue worldwide. Cancer patient are at increased risk of infection compared to general population. On the other hand, these patients are at major risk of drug interactions caused by renal and hepatic impairment background. Because of the long-term use of chemotherapy drugs, drug interactions are important in these patients especially with SARS-CoV2 treatments now. This paper is review of reported drug interactions of current treatments for COVID-19 and anticancer agents.
摘要
SARS-CoV2 感染是全球范围内的一个新出现的问题。与一般人群相比，癌症患者感染的风险更高。另一方面，这些患者由于肾功能和肝功能受损，药物相互作用的风险很大。由于长期使用化疗药物，药物相互作用在这些患者中很重要，特别是在目前针对 SARS-CoV2 的治疗中。本文综述了目前 COVID-19 治疗药物和抗癌药物的药物相互作用报道。
相似文献
1
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.
Crit Rev Oncol Hematol. 2020 Jul;151:102982. doi: 10.1016/j.critrevonc.2020.102982. Epub 2020 May 12.
2
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Eur J Cancer. 2020 Sep;136:1-3. doi: 10.1016/j.ejca.2020.05.027. Epub 2020 Jun 10.
3
Management of COVID-19 in people with epilepsy: drug considerations.
Neurol Sci. 2020 Aug;41(8):2005-2011. doi: 10.1007/s10072-020-04549-5. Epub 2020 Jun 27.
4
Considerations for Statin Therapy in Patients with COVID-19.
Pharmacotherapy. 2020 May;40(5):484-486. doi: 10.1002/phar.2397. Epub 2020 May 4.
5
COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.
Crit Rev Oncol Hematol. 2020 Aug;152:102991. doi: 10.1016/j.critrevonc.2020.102991. Epub 2020 May 21.
6
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761.
7
[Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):400-404. doi: 10.3760/cma.j.cn112138-20200219-00097.
8
Interactions of recommended COVID-19 drugs with commonly used psychotropics.
Asian J Psychiatr. 2020 Aug;52:102173. doi: 10.1016/j.ajp.2020.102173. Epub 2020 May 21.
9
[Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].
Encephale. 2020 Jun;46(3S):S14-S34. doi: 10.1016/j.encep.2020.04.006. Epub 2020 May 4.
10
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.
引用本文的文献
1
Favipiravir-induced bradycardia: A case report.
Clin Case Rep. 2024 Jun 27;12(7):e9052. doi: 10.1002/ccr3.9052. eCollection 2024 Jul.
2
Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition.
Sci Rep. 2024 Jan 22;14(1):1844. doi: 10.1038/s41598-024-51977-w.
3
Evaluation of clinical outcomes, laboratory and imaging data of patients with solid tumor infected with COVID-19 infection.
Int J Biochem Mol Biol. 2022 Dec 15;13(6):77-86. eCollection 2022.
4
Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.
Front Pharmacol. 2022 Feb 21;13:817715. doi: 10.3389/fphar.2022.817715. eCollection 2022.
5
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.
J Oncol Pharm Pract. 2022 Dec;28(8):1737-1748. doi: 10.1177/10781552211040494. Epub 2021 Oct 12.
6
Recommendations for developing clinical care protocols during pandemics: From theory and practice.
Best Pract Res Clin Anaesthesiol. 2021 Oct;35(3):461-475. doi: 10.1016/j.bpa.2021.02.002. Epub 2021 Feb 27.
7
Pain management in COVID-19 pediatric patients-An evidence- based review.
Saudi J Anaesth. 2021 Jan-Mar;15(1):33-39. doi: 10.4103/sja.SJA_635_20. Epub 2021 Jan 5.
8
Science's Response to CoVID-19.
ChemMedChem. 2021 Aug 5;16(15):2288-2314. doi: 10.1002/cmdc.202100079. Epub 2021 Jun 22.
9
An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
Front Pharmacol. 2021 Mar 8;12:632677. doi: 10.3389/fphar.2021.632677. eCollection 2021.
10
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
Arch Med Res. 2021 Apr;52(3):261-269. doi: 10.1016/j.arcmed.2020.11.006. Epub 2020 Nov 17.
本文引用的文献
1
Interleukin-6 in Covid-19: A systematic review and meta-analysis.
Rev Med Virol. 2020 Nov;30(6):1-9. doi: 10.1002/rmv.2141. Epub 2020 Aug 26.
2
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
3
Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
4
Covid-19 - The Search for Effective Therapy.
N Engl J Med. 2020 May 7;382(19):1851-1852. doi: 10.1056/NEJMe2005477. Epub 2020 Mar 18.
5
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
6
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
7
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
8
Remdesivir as a possible therapeutic option for the COVID-19.
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
9
Risk of COVID-19 for patients with cancer.
Lancet Oncol. 2020 Apr;21(4):e181. doi: 10.1016/S1470-2045(20)30149-2. Epub 2020 Mar 3.
10
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.
Zotero 插件